Cooperative Agreement UG1CA308665
Award Date 4/28/26
Completion Date 2/29/32
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Chicago, IL 60611, USA
Similar Awards
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a $2.67 million Cooperative Agreement to MedStar Health Research Institute Inc. on July 25, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to improve the delivery of geriatric assessment in community oncology settings. The project addresses the critical need to implement evidence-based geriatric assessment practices among older adults aged 65 and older with cancer, who represent 75% of...
- Federal Cooperative Agreement Award Summary The University of Pennsylvania's Abramson Cancer Center (ACC) received a Cooperative Agreement award of $368,701.00 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 20, 2026, with a completion date of February 29, 2032. This award supports the ACC's leadership role as a Lead Academic Participating Site (LAPS) within the NCI's National Clinical Trials Network (NCTN). Under the...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded Indiana University's Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC) a cooperative agreement valued at $366,921.00, effective April 20, 2026, through February 29, 2032, under the Cancer Treatment Research program (CFDA 93.395). As a lead academic participating site within the National Clinical Trial Network (NCTN), IUSCCC will provide coordinated clinical trial infrastructure and translational research...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement valued at $639,882 to the University of North Carolina at Chapel Hill (UNC-CH), Office of Sponsored Research, effective August 1, 2025, through July 31, 2030, under the Cancer Biology Research program (CFDA 93.396). This award supports fundamental research into the molecular mechanisms underlying metastasis organ tropism—specifically, why certain breast cancer subtypes preferentially...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded $941,798 to Beckman Research Institute of the City of Hope under the Cancer Biology Research program (CFDA 93.396) on August 6, 2025, for a five-year initiative concluding July 31, 2030. This cooperative agreement supports fundamental research investigating the mechanism and therapeutic implications of RNA-modification-mediated codon-biased translation in acute myeloid leukemia (AML). The research focuses on...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded The Institute For Cancer Research a Cooperative Agreement totaling $263,670 under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on May 1, 2026, with completion scheduled for April 30, 2028. The award funds clinical translation of a urine-based biomarker test for detecting residual disease in radical cystectomy candidates. The project develops and validates a Noninvasive Test for Assessment of...
- Federal Cooperative Agreement Summary The University of Michigan received a $210,600 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), effective September 1, 2025, through August 31, 2027. This award supports the analytical and clinical validation of an H3K27M circulating tumor DNA (ctDNA) assay designed to improve disease monitoring and early detection of progression in diffuse midline glioma (DMG) patients. The...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded a $2.56 million Cooperative Agreement (CFDA 93.397, Cancer Centers Support Grants program) to The University of Texas MD Anderson Cancer Center for a Lymphoma Outcomes SPORE (Specialized Program of Research Excellence) addressing health disparities in lymphoma outcomes across African American and Hispanic patient populations. The award, effective August 22, 2025, through July 31, 2030, supports an integrated research...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a Cooperative Agreement totaling $962,104 to the Research Institute at Nationwide Children's Hospital, with an award date of July 3, 2025, and completion date of June 30, 2029, under the Cancer Treatment Research program (CFDA 93.395). This agreement supports the development and clinical testing of novel therapeutic approaches targeting mutant-MYOD1 driven rhabdomyosarcoma (RMS), the most common soft tissue...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded a $1,219,056 Cooperative Agreement to Harvard Medical School (President and Fellows of Harvard College) under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, with a completion date of September 26, 2025. The award funds research to optimize pre-analytical tumor handling conditions for Ramp Up Dynamic BH3 Profiling (RUDBP), a functional precision medicine biomarker used to identify ideal...